List of Imaging Agents That Are FDA-Approved or Currently in Clinical Trials in IMI
| Imaging agent | Fluorochrome | Excitation (nm) | Emission (nm) | Molecular target | Mechanism |
|---|---|---|---|---|---|
| SGM-101 | BM-104 (6,54) | 685 | 705 | Carcinoembryonic antigen (CEA) | Active |
| LUM015 | Cy5 (13) | 650 | 675 | Cathepsins, MMP | Activatable |
| Pegloprastide (AVB-620) | Cy5 and Cy7 (55) | 630 | 620–850 | MMP | Activatable |
| Fluorescein | Fluorescein | 494 | 521 | N/A | Passive |
| EC17 | Fluorescein derivative (9,56) | 470 | 520 | Folate-receptor alpha | Active |
| ALM-488 | Fluorescein derivative (9) | 488 | 530 | Nerve cell membrane | Active |
| gGlu-HMRG | Hydroxymethyl rhodamine green (HMRG) (57) | 500 | 524 | γ-glutamyl transpeptidase | Activatable |
| Indocyanine Green (ICG) | ICG (58) | 780 | 805 | N/A | Passive |
| TumorGlow | ICG (9) | 780 | 805 | N/A | Passive |
| BLZ-100 (Tozuleristide; TumorPaint) | ICG (18) | 780 | 805 | Annexin A2, MMP2 | Active |
| Pegsitacianine (ONM 100) | ICG (14) | 780 | 805 | N/A | Activatable |
| Bevacizumab-IRDye800CW | IRDye800CW (36) | 775 | 805 | VEGF-A | Active |
| Cetuximab-IRDye800CW | IRDye800CW (41) | 775 | 805 | EGFR | Active |
| Panitumumab-IRDye800CW | IRDye800CW (42) | 775 | 805 | EGFR | Active |
| ABY-029 | IRDye800CW (59) | 775 | 805 | EGFR | Active |
| Methylene Blue | Methylene Blue | 668 | 688 | N/A | Passive |
| 5-Aminolevulinic Acid (5-ALA; Gleolan) | Protoporphyrin IX (15) | 405 | 635 | N/A | Passive |
| Pafolacianine (OTL38) | S0456 (10) | 774 | 794 | Folate-receptor alpha | Active |
| OTL78 | S0456 (60) | 774 | 794 | Prostate specific membrane antigen (PSMA) | Active |
MMP = matrix metalloproteinase; N/A = not applicable; VEGF = vascular endothelial growth factor.